The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics has announced the appointment of Martine Zimmermann to its board of directors. Zimmermann brings more than 30 years of experience in regulatory affairs and quality management across multiple stages of drug development.
Her expertise is expected to enhance Candel Therapeutics leadership as the company advances its pipeline through various regulatory and commercial phases.
View post on X Loading...
Candel Therapeutics recently shared new immune response data for aglatimagene in localized prostate cancer, reinforcing phase 3 trial outcomes in a previous update. The company is also set to present new data on aglatimagene besadenovec and linoserpaturev at the SITC annual meeting in November, according to a recent announcement. These developments mark ongoing efforts to advance its pipeline through clinical stages.